Tirzepatide Expands Its Reach: Cardiovascular Protection and Sleep Apnea Approval Mark a New Chapter

A Dual Agonist With Growing Indications

Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, has cemented its position as one of the most consequential peptide therapeutics of the decade. Originally approved for glycemic control in adults with type 2 diabetes, the GIP/GLP-1 dual receptor agonist has steadily accumulated new indications, clinical evidence, and market momentum throughout 2025 and into 2026.

The most significant regulatory milestone came when the FDA approved Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on data from the SURMOUNT-OSA Phase 3 trial, which enrolled 469 participants and demonstrated that tirzepatide at 15 mg achieved a mean reduction of 27.4 breathing disruptions per hour compared to 4.8 with placebo. Patients not using CPAP therapy saw roughly five times greater improvement than those on placebo, while a concurrent 20.1 percent weight reduction underscored the metabolic mechanism driving the benefit.

Cardiovascular Outcomes: Head-to-Head Victory

The SURPASS-CVOT trial, published in the New England Journal of Medicine in December 2025, provided definitive cardiovascular safety and efficacy data. In a head-to-head comparison involving more than 13,000 adults with type 2 diabetes, tirzepatide demonstrated non-inferiority to dulaglutide with an 8 percent lower rate of major adverse cardiovascular events over a median four-year follow-up period. While not controlled for multiplicity-adjusted type-1 error, secondary endpoints showed improvements in A1C, weight, renal function, and all-cause mortality.

The cardiovascular data positions tirzepatide as a serious contender for cardiometabolic risk reduction, a space historically dominated by semaglutide following the SELECT trial. Discontinuation rates due to adverse events were 13.3 percent for tirzepatide versus 10.2 percent for dulaglutide, predominantly gastrointestinal in nature.

Pediatric Expansion

Lilly also reported positive Phase 3 results from the SURPASS-PEDS trial evaluating tirzepatide in children and adolescents aged 10 to 17 with type 2 diabetes. The trial met its primary and all key secondary endpoints, demonstrating superior improvements in A1C and body mass index compared to placebo. This data supports a potential label expansion that could make tirzepatide the first dual agonist approved for pediatric diabetes.

Market Implications

With clinical evidence spanning diabetes, obesity, obstructive sleep apnea, cardiovascular protection, and pediatric populations, tirzepatide is rapidly becoming a franchise drug for Eli Lilly. Analysts estimate the combined Mounjaro and Zepbound revenue could exceed $25 billion annually by 2027. Meanwhile, Novo Nordisk's amycretin, a GLP-1/amylin dual agonist that showed 14.5 percent weight loss in a Phase 2 trial announced in November 2025, is entering Phase 3 in early 2026 and could introduce meaningful competition.

For clinicians and patients, the expanding evidence base means tirzepatide is no longer just a diabetes medication. It is becoming a platform therapy for cardiometabolic disease, with additional indications likely to follow as ongoing trials in MASH, heart failure, and chronic kidney disease mature.